Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer by Bella Pajares et al.
Pajares et al. BMC Cancer 2013, 13:26
http://www.biomedcentral.com/1471-2407/13/26RESEARCH ARTICLE Open AccessDifferential outcome of concurrent radiotherapy
plus epidermal growth factor receptor inhibitors
versus radiotherapy plus cisplatin in patients
with human papillomavirus-related head
and neck cancer
Bella Pajares1*†, Jose M Trigo1†, Maria D Toledo2, Martina Álvarez3, Carlos González-Hermoso4, Antonio Rueda5,
Jose A Medina2, Vanessa de Luque6, Jose M Jerez7 and Emilio Alba1Abstract
Background: Human papillomavirus (HPV)-related head and neck cancer has been associated with an improved
prognosis in patients treated with radiotherapy (RT) +/− chemotherapy (CT); however, RT combined with epidermal
growth factor receptor (EGFR) inhibitors has not been fully studied in this group of patients.
Methods: Immunohistochemical expression of p16 and PCR of HPV16 DNA were retrospectively analyzed in tumor
blocks from 108 stage III/IV head and neck cancer patients treated with RT+CT (56) or RT+EGFR inhibitors (52).
Disease-free survival (DFS) and overall survival (OS) were analyzed by the Kaplan-Meier method.
Results: DNA of HPV16 was found in 12 of 108 tumors (11%) and p16 positivity in 18 tumors (17%), with similar
rates in both arms of treatment. After a median follow-up time of 35 months (range 6–135), p16-positive patients
treated with RT+EGFR inhibitors showed improved survival compared with those treated with RT+CT (2-year OS
88% vs. 60%, HR 0.18; 95% CI 0.04 to 0.88; p = 0.01; and 2-year DFS 75% vs. 47%, HR 0.17; 95% CI 0.03 to 0.8;
p = 0.01). However, no differences were observed in p16-negative patients (2-year OS 56% vs. 53%, HR 0.97; 95%
CI 0.55 to 1.7; p = 0.9; and 2-year DFS 43% vs. 45%, HR 0.99; 95% CI 0.57 to 1.7; p = 0.9).
Conclusions: This is the first study to show that p16-positive patients may benefit more from RT+EGFR inhibitors
than conventional RT+CT. These results are hypothesis-generating and should be confirmed in prospective trials.
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Head and neck squamous cell carcinoma (HNSCC) is
the sixth most common cancer worldwide, with an esti-
mated annual burden of 633,000 incident cases and
355,000 deaths [1]. This neoplasm is largely attributed
to environmental exposures, such as tobacco and alco-
hol consumption [2]. However, a subset of HNSCC,
specifically oropharyngeal squamous cell carcinomas* Correspondence: bella.pajares@fundacionimabis.org
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reproduction in any medium, provided the or(OPSCCs) located in the base of the tongue and in the
tonsils, and less frequently oral cavity and hypopharynx
squamous cell carcinomas, may occur in non-smokers
and non-drinkers, suggesting the presence of other risk
factors. Recent epidemiological and molecular studies
suggest that human papillomavirus (HPV) infection, the
necessary cause of cervical carcinoma, is involved in the
pathogenesis of a subset of these neoplasms [3-7].
HPV genomic DNA has been found in approximately
20-25% of all HNSCCs using sensitive polymerase chain
reaction (PCR)-based methods, with a greater prevalence in
OPSCC (36-75%) [4,8-11], and p16INK4A (p16) overexpres-
sion has also been correlated with HPV positivity [12-16].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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retrospective analyses of prospective studies and phase
III trials, have shown that patients with HPV-related
HNSCC managed with radiotherapy (RT) +/− chemo-
therapy (CT) have better prognosis compared with
patients with HPV-negative tumors in terms of response
and survival [13,14,17-21]. This benefit has also been
observed in p16-positive patients compared with p16-
negative patients [14,21-24]. Moreover, a recent meta-
analysis with more than 5,600 patients from 34 studies
showed a better prognosis in terms of survival for HPV-
positive HNSCC (HR, 0.42; 95% CI 0.27 to 0.57;
p < 0.0001), specially in OPSCCs (HR, 0.4; 95% CI 0.18
to 0.61; p < 0.0001) [25]. All these studies involved
patients treated with different protocols, including differ-
ent combinations of RT and CT.
Over the past decade, clinical research on HNSCC has
focused on improving the efficacy of current multimodal
approaches and decreasing toxicity by targeting cellular
pathways associated with carcinogenesis. Blocking the
epidermal growth factor receptor (EGFR) has emerged
as a primary strategy, although not much information is
available about these therapies in HPV-positive patients.
In the present study, we aimed to retrospectively evalu-
ate the impact of p16 expression and HPV16 DNA posi-
tivity on response and survival in patients with HNSCC
treated with a combination of RT plus EGFR inhibitors
compared with patients treated with RT+CT.
Materials and methods
Patient data and specimen characteristics
Between 2000 and 2011, 116 patients with newly diagnosed
locally advanced HNSCC (stage III and IV non-metastatic)
who were candidates for radical RT combined with CT or
EGFR inhibitors were treated under different protocols in
our center. A total of 108 patients were fully assessable in
terms of availability of pathological specimens. Baseline
studies included physical examination, chest X-rays, endos-
copy of the upper aerodigestive tract and computed tomo-
graphy of the neck. The response to the treatment was
assessed 6–8 weeks after the end of therapy by RECIST
criteria. After treatment, all patients underwent clinical
examinations and imaging on a regular basis. We also
assessed reliable information about tobacco exposure and
alcohol consumption. Patients were assessed for the occur-
rence of HNSCC relapse, second tumors (ST) and death.
ST was clinically defined as a tumor occurring more than 2
centimeters away and more than 3 years after the treatment
of the primary tumor. Fifty-six patients received concurrent
RT plus platinum-based CT, and 52 patients received
several types of EGFR inhibitors, mainly cetuximab,
concurrent with RT.
CT was administered as three-weekly cisplatin doses of
100 mg/m2 (32 pts.) or weekly cisplatin at 40 mg/m2(24 pts.). EGFR inhibitors were mainly administered as
weekly cetuximab at an initial dose of 400 mg/m2 followed
by 250 mg/m2 (36 pts.), three-weekly panitumumab at 9
mg/kg (11 pts.) or daily gefitinib at 250 mg/day (5 pts.).
Radiation treatment was delivered with curative intention
to the whole series by the technique of three-dimensional
conformal radiotherapy. The median dose of radiotherapy
was 72 Gy (57–78 Gy). Ninety-seven patients received
accelerated fractionation with concomitant boost, and 11
patients were treated with standard fractionation. Standard
fractionation was administered in 1.8 or 2 Gy per fraction,
5 fractions a week to 70 Gy in 35 fractions over 7 weeks.
Accelerated fractionation with concomitant boost was
delivered in 1.8 Gy per fraction, 5 fractions a week to 54 Gy
in 30 fractions over 6 weeks, to the initial target volume
encompassing the gross tumor and clinically/radiologically
involved nodes along with regions of potential contiguous
and lymphatic spread. At 32.4 Gy, a second daily dose of
1.5 Gy per fraction (with an interval of at least 6 hours) was
given to the boost volume covering the gross tumor and
involved nodes for a total of 18 Gy in 12 treatment days.
The primary tumor and clinically/radiologically involved
nodes received 72 Gy in 42 fractions over 6 weeks, and
uninvolved nodes received 54 Gy over 6 weeks. During the
treatment, patients were seen at least weekly by a radiation
oncologist or medical oncologist and more frequently when
necessary. The median follow-up time was 35 months
(range 6–135).
Statistical analysis
Patients, toxic habits, type of treatment and disease charac-
teristics were tabulated by means of frequency tables.
Qualitative variables are expressed as a percentage with a
95 confidence interval of the percentage, and quantitative
variables are expressed as the median and range. Variable
comparisons were carried out using the Wilcoxon or chi-
square tests. The end points of interest were overall survival
(OS), disease-free survival (DFS) and tumor relapse. OS
was defined as the time from first treatment to death due
to any cause. DFS was defined as the time from first treat-
ment to first documented relapse, secondary tumor or
death by any cause. Tumor relapse was defined as head and
neck cancer recurrence any time after RT+CT treatment.
To investigate the pattern of occurrence over time of any of
the aforementioned end points, descriptive analyses were
carried out by estimating Kaplan-Meier survival curves,
whereas inferential analyses relied on cumulative hazards.
In particular, unadjusted p values for testing the prognostic
effect of HPV16 DNA and p16 overexpression status were
obtained from the log rank test, and adjusted p values were
obtained from the likelihood ratio test in a multivariable
Cox regression model. p values below the conventional 5%
threshold were regarded as significant. All the analyses were
carried out using R and SPSS version 15.0 software.
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p16 immunohistochemistry (IHC) was performed on for-
malin-fixed, paraffin-embedded (FFPE) tissue sections using
a CINtecW Histology Kit (mtm laboratories AG, Germany)
for the qualitative detection of the p16 (antibody clone
E6H4 TM) in a Dako autostainer (Dako, Copenhagen,
Denmark). Cervical cancer sections known to be p16 posi-
tive were used as positive controls, and omission of primary
antibody was used as the negative control. All p16 IHC
biopsies were semiquantitatively scored by a pathologist
blinded to the patient’s HPV status. Tumors were classified
dichotomously as either p16-positive (strong, diffuse stain-
ing) or p16-negative.
HPV Polymerase chain reaction
FFPE tissue sections were assessed by a pathologist to
determine the percentage of tumor in each section. DNA
was extracted using a DNA Blood mini kit (Promega). HPV
was detected by PCR by using a PapType human papillo-
mavirus detection test (Kit Screening HPV, Master
Diagnostica S.L.) using the primer Gp 5-6/L1. Then, the
positive cases were genotyped to detect the specific HPV
subtype (HPV GenoArray Test Kit, Master Diagnóstica
S.L.). This assay detects 17 subtypes of high-risk HPV
(16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73
and 82) and 16 low-risk HPV subtypes (6, 11, 40/61, 42, 43/
44, 54/55, 70, 57/71, 72, 81, and 84/26). All samples were
amplified in duplicate to provide a control of method
reproducibility.
Ethics statement
This study was carried out in compliance with the Declar-
ation of Helsinki (http://www.wma.net/en/30publications/
10policies/b3/index.html). All subjects provided informed
consent for study inclusion, and the study was approved by
our hospital's ethics committee (Comité de Etica del
Hospital Virgen de la Victoria, Málaga, Spain).
Results
Patient characteristics
The vast majority of patients in both groups were male
smokers with ECOG 1 performance status and stage IV
disease at the time of diagnosis. Twenty-two patients were
HPV positive: 17 for high-risk HPV (HPV16, 18, 51 and
58), 3 for low-risk HPV (HPV5 and 6) and 2 for unknown
subtypes (Table 1). Twelve of 108 patients were HPV16
positive (11%). Eighteen of 108 cases were p16 positive
(17%), and a strong association was found between HPV16
DNA detection and p16 expression. Eight of 12 HPV16-
positive tumors exhibited strong and diffuse p16 staining,
whereas only 10 of 96 HPV16-negative tumors were p16
positive (67 vs. 10.4%; p < 0.0001) (Table 1). Table 1 shows
patient and tumor characteristics according to p16 status.
Patients who were p16 positive were less likely to besmokers than p16-negative patients (p < 0.04). The expres-
sion of p16 was higher in OPSCCs than in non-OPSCCs
(p = 0.04). Table 2 shows patient characteristics according
to treatment received. The rate of p16 positivity was similar
in both treatment arms: in the group of patients treated
with RT+EGFR inhibitors, the rate of positivity was 15%
(8/52), and in the group treated with conventional RT+CT,
the rate of positivity was 18% (10/56). There were signifi-
cantly more women and less alcohol consumption in the
group of patients treated with RT+EGFR inhibitors com-
pared with the group treated with RT+CT (p < 0.05). On
the other hand, there were more patients with an oral cavity
location in the group treated with RT+CT (p < 0.05). The
proportion of patients treated with standard fractionation
was higher in the group treated with EGFR inhibitors
compared with those treated with CT (p < 0.003).Efficacy
Response
The complete response (CR) rates among p16-positive vs.
p16-negative cases were 89% and 74%, respectively
(OR = 2.7; 95% CI 1.6 to 12.8; p = 0.2) (Table 1). In the 18
patients with p16 expression, those treated with RT+EGFR
inhibitors showed a similar CR rate compared with those
treated with RT+CT, with CR rates of 100% (8/8) vs. 80%
(8/10) respectively; (OR = 2; 95% CI 1.6 to 3.2; p = 0.4).
The p16-negative patients showed CR rates of 75% (33/44)
when treated with RT+EGFR inhibitors and 74% (34/46)
when treated with RT+CT (OR = 1.05; 95% CI 0.4-2.7;
p = 1).Recurrences
With a median follow-up time of 35 months (range 6–135),
we observed 48 recurrences: 39 locoregional failures and 9
distant failures. Seven patients developed a second tumor
(three lung cancer, two gastric cancer, one tongue tumor
and one renal tumor). The group of patients with p16
expression showed a 2-year recurrence rate of 28% (5/18),
compared to 48% (43/90) among p16-negative patients
(HR = 0.4; 95% CI 0,1 to 1.2; p = 0.2). Similar results were
also observed for locoregional recurrence, with 2-year
locoregional recurrence rates of 22% (4/18) and 39%
(35/90),respectively (HR = 0.4; 95% CI 0.1 to 1.4; p = 0.3).
These differences were statistically significant for OPSCCs,
with a risk of recurrence at 2 years of 11% (1/9) for p16-
positive patients vs. 50% (15/30) for p16-negative patients
(p = 0.05). In the group of patients with p16-positive
tumors, those treated with RT+EGFR inhibitors showed a
2-year recurrence rate of 13% (1/8), which was not signifi-
cantly different from the 40% (4/10) for those treated with
RT+CT (HR = 0.2; 95% CI 0.01-2.4; p = 0.3). p16-negative
patients treated with RT+EGFR inhibitors showed a 2-year
recurrence rate of 46% (20/44), which was similar to the
Table 1 Patient and tumour characteristic by p16
expression status
p16 Negative p16 Positive
Patient/Tumour Data No. % No. % p
Nº of patients 90 18
Age, years
Median 59 57 NS
Range 33-84 44-77
Sex
Male 84 93 17 94 NS
Female 6 7 1 6
Current smokers
No 3 3 3 16
Yes 67 74 10 55 0.01
Unknown 20 23 5 29
Alcohol consumption
No 10 11 3 16
Yes 57 63 10 55 NS
Unknown 23 26 5 29
Performance status
ECOG 0 36 40 9 50 NS
ECOG 1 43 48 8 44
ECOG 2 11 12 1 6
Tumor site
Oral cavity 14 16 2 11 0.04
Oropharynx 30 33 9 50
Larynx 36 40 2 11
Hypopharynx 10 11 5 28
PCR - HPV status
HR-HPV (16,18,51,58) 8 9 9 50
LR-HPV (5,6) 2 2 1 5.5 0.0001
Unknown subtype 1 1 1 5.5
Negative 79 88 7 39
Grade
Well/Moderate 40 44 6 33 NS
Poor 9 10 2 11
Unknown 41 46 10 56
Tumour stage
T1-T3 37 41 5 28 NS
T4 53 59 13 72
Nodal status
No 28 31 5 28 NS
N+ 62 69 13 72
Stage
III 28 31 6 33 NS
IV 62 59 12 67
Table 1 Patient and tumour characteristic by p16
expression status (Continued)
Treatment
RT-CT 46 51 10 56 NS
RT-EGFR inhibitors 44 49 8 44
Irradiation dose
Mean 71 71.4 NS
Range 57-78 70-74
Type of radiotherapy
Conventional RT 11 12 0 0 NS
Concomitant boost 79 88 18 100
Response
Complete response 67 74 16 89
Partial response 16 18 0 0 NS
Stable disease 1 1 1 5.5
Progression 0 0 1 5.5
Unknown 6 7 0 0
Median OS (months) 32 54 NS
Range 14-50 20-87
Median DFS (months) 18 52 NS
Range 13-24 0-103
Abbreviation: NS, not significant.
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0.4-1.9; p = 0.7).Survival
At the end of follow-up, 67 patients had died: 54 because of
primary cancer, 13 because of other causes and 5 patients
because of loss to follow-up. Trends for better OS and DFS
were observed in the p16-positive group compared with
p16-negative patients, with a median OS of 54 vs. 32
months (HR = 0.65; 95% CI 0.3 to 1.2; p = 0.18) and a
median DFS of 52 vs.18 months (HR = 0.57; 95% CI 0.28 to
1.1; p = 0.1). These differences were statistically significant
in the oropharyngeal location, with 2-year OS rates of 89%
for p16-positive patients and 59% for p16-negative patients
(HR = 0.3; 95% CI 0.09 to 0.9; p = 0.04) and respective
2-year DFS rates of 67% and 48% (HR = 0.3; 95% CI 0.09 to
0.9; p = 0.05) (Figure 1).
The p16-positive patients treated with RT+EGFR inhibi-
tors showed improved survival compared with those trea-
ted with RT+CT (2-year OS: 88% vs. 60%; HR = 0.18, 95%
CI 0.04 to 0.88; p = 0.01; 2-year DFS: 75% vs. 47%
HR = 0.17, 95% CI 0.03 to 0.8; p = 0.01). However, no sur-
vival differences were observed in p16-negative patients
treated with RT+EGFR inhibitors compared with those
treated with RT+CT (2 year OS: 56% vs. 53%; HR = 0.97;
Table 2 Patient and tumour characteristic by group of
treatment
CT-RT RT-EGFRinhibitors
Patient/Tumour Data No. % No. % p
Nº of patients 56 52
Age, years
Median 58 60 NS
Range 44-74 33-84
Sex
Male 55 98 46 89 0.05
Female 1 2 6 11
Current smokers
No 3 5 3 6 NS
Yes 28 50 49 94
Unknown 25 45 0 0
Alcohol consumption
No 1 2 12 23
Yes 28 50 39 75 0.02
Unknown 27 48 1 2
Performance status
ECOG 0–1 51 91 45 87 NS
ECOG 2-3 5 9 7 13
Tumor site
Oral cavity 13 23 3 6
Oropharynx 16 29 23 44 0.02
Larynx 17 30 21 40
Hypopharynx 10 18 5 10
Grade
Well/Moderate 34 61 12 23 NS
Poor 5 9 6 12
Unknown 17 30 34 65
Tumour stage
T1-T3 20 36 30 58 NS
T4 36 64 22 42
Nodal status
N0-N1 24 43 32 61 NS
N2-N3 32 57 20 39
P16 expression
negative 46 82 44 85 NS
positive 10 18 8 15
HPV16 expression
negative 50 89 46 88 NS
positive 6 11 6 12
Irradiation dose 71.2 71 NS
Mean 57-72 70-78
Range
Table 2 Patient and tumour characteristic by group of
treatment (Continued)
Type of radiotherapy
Conventional RT 1 2 10 19 0.003
Concomitant boost 55 92 42 81
Response
Complete response 42 75 41 79
Partial response 8 14 8 15 NS
Stable disease 2 4 0 0
Progression 1 2 0 0
Unknown 3 5 3 6
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HR = 0.99; 95% CI 0.57 to 1.7; p = 0.9) (Figure 2).
Similarly, HPV16-positive patients treated with RT+EGFR
inhibitors showed improved survival compared with those
treated with RT+CT (2-year OS: 83% vs. 33%; HR = 0.22,
95% CI 0.05 to 0.9; p = 0.02; 2-year DFS: 50% vs. 17%; HR =
0.19, 95% CI 0.47 to 0.8; p = 0.01). However, no survival dif-
ferences were observed in HPV16-negative patients treated
with RT+EGFR inhibitors compared with those treated with
RT+CT (2-year OS: 58% vs. 57%; HR = 0.83; 95% CI 0.48 to
1.45; p =.0.5; 2-year DFS: 48% vs. 49%; HR = 0.9; 95% CI
0.53 to 1.5; p = 0.7). In the Cox regression analysis with OS
and DFS as the end points, when adjusting for ECOG per-
formance status, tumor size, N category and p16 expres-
sion, N category was the only prognostic factor
independently associated with a good prognosis in the
multivariable analysis (data not shown).Discussion
In the present study, we analyzed the association of tumor
p16 expression with prognosis in a retrospectively collected
cohort of patients with HNSCC treated with RT+EGFR
inhibitors or RT+CT. A strong correlation between HPV16
status and p16 immunostaining was found, as well as a
significant benefit in OS and DFS for p16-positive OPSCC
patients. Our most interesting result is the significant bene-
fit in OS and DFS for p16-positive patients when treated
with RT+EGFR inhibitors compared with conventional
RT+CT (p = 0.01), whereas this benefit was not observed
in p16-negative patients (p = 0.9). From 2000 to 2011, more
than 304 patients were treated in our center with RT plus
platinum-based CT. To ensure this study provided results
from a representative sample of our patients, we assessed
the OS rates of the entire group. The median OS of these
304 patients was 37 months (range of 21–53 months), with
2- and 5-year OS rates of 56% and 37%, respectively. These
results are similar to those observed for the group of 108
patients analyzed in this study, who had a median OS of 32
Figure 1 Kaplan-Meier estimates of survival among OPSCC patients according to p16 expression. Panels A and B show the benefits in OS
and DFS, respectively, in patients with p16-positive OPSCC compared with p16-negative OPSCC (p = 0.04 and 0.05, respectively).
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rates of 58% and 35%, respectively.
We found HPV16 DNA in 11% of the patients and in
15% of the OPSCCs. Both of these prevalences are lower
compared with data from a recent meta-analysis (22-34% in
HNSCC and 30-41% in OPSCC) [8,10,25], possibly due to
the epidemiologic profile of our population, which had a
high proportion of former/current and heavy tobacco users.
Several studies have confirmed a better outcome for
patients with HPV-positive HNSCC compared with
HPV-negative patients. The majority of these studies
have been performed in OPSCC, so this benefit is well
established in this subset of tumors [13,14,17-21]. A re-
cent meta-analysis of 34 studies published by Dayyani
et al. has shown a benefit in OS for HPV-positive
patients compared to HPV-negative patients (HR = 0.4;
95% CI 0.2 to 0.6; p = 0.0001), including all locations of
HNSCC [25]. According with these data, several studies
have shown that among patients with HNSCC and
OPSCC managed with different treatment modalities,
those with p16-positive tumors have a better prognosis
in terms of response, recurrence and survival than
patients with p16-negative tumors [14,22-24]. Recently,
the results of a phase III clinical trial (TROG 02.02) with
concurrent RT+CT with or without tirapazamine has
shown promising results in the subgroup of patients
with OPSCC using p16 immunohistochemistry as a
prognostic factor. Patients with p16-positive tumors had
better 2-year OS and failure-free survival (FFS) rates
compared with patients with p16-negative tumors
(OS 91% vs. 74%; p = 0.04; FFS 87% vs. 72%; p = 0.003).
Cox regression analysis of OS, including the prognostic
factors of hemoglobin, T category, N category, and
ECOG performance status, demonstrated that p16 statuswas the only significant factor in multivariable analysis
(HR = 0.4; 95% CI 0.2 to 0.9; p = 0.03) [24].
The HPV-related beneficial outcome in this neoplasm
indicates that these tumors respond well to conventional
treatment approaches. The biologic basis for this observa-
tion is under investigation, but it could be due to some
extent to an increased sensitivity to RT+CT of functional,
non-mutated p53 [26] and the absence of field canceriza-
tion related to tobacco/alcohol exposure. Moreover, an
increased sensitivity to apoptosis has been observed in
E6/E7-positive human keratinocytes when exposed to
cisplatin-based CT [4,27]. To the best of our knowledge,
only one study has reported differences in survival in
patients treated with EGFR inhibitors according to p16 or
HPV16 status [28] That phase II trial, which applied
induction CT based on paclitaxel, carboplatin and cetuxi-
mab followed by either RT, concomitant RT+CT, or
surgery, for locally advanced (LA)-HNSCC, shows a
robust benefit in survival for HPV-positive patients over
HPV-negative patients, with improved progression-free
survival (p = 0.012) and OS (p = 0.046). The current study
supports this better outcome for HPV-positive patients
regardless the treatment received.
Our study found a better outcome in terms of DFS and
OS in p16-positive patients treated with RT+EGFR inhi-
bitors compared with those treated with conventional
RT+CT. The reason for these findings remains unclear.
An inverse relationship between HPV status and EGFR
expression has been demonstrated in several recent
head and neck cancer studies [15,29-31]. Most of them
suggest that a combination of HPV and EGFR may more
accurately predict the outcome of patients than either
alone. One recent study examined the prognostic sig-
nificance of EGFR in relation to HPV in a large cohort
A.
B.
OS-p16 positive patients according to treatment received C. 
D. 
OS-p16 negative patients according to treatment received
 
 DFS-p16 positive patients according to treatment received DFS-p16 negative patients according to treatment received 
2-year OS 88% vs. 60% 
p=0.01 
2-year OS 56% vs. 53% 
p=0.9 
2-year DFS 75% vs. 47% 
p=0.01 
2-year DFS 43% vs. 45% 
p=0.9 
Figure 2 Kaplan-Meier estimates of survival according to p16 expression and treatment received. Panels A and B show OS and DFS,
respectively, for p16-positive patients according to the treatment received. Patients with p16-positive tumors treated with RT+EGFR inhibitors had
significantly better OS and DFS than those treated with RT+CT (p = 0.01 for both comparisons by the two-sided log-rank test). Panels C and D
show OS and DFS, respectively, for p16-negative patients according to the treatment received. No benefit in OS or DFS was observed in these
patients when treated with RT+EGFR inhibitors compared to RT+CT (p = 0.9).
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was a predictor of loco-regional recurrence, event-free
survival, and OS after adjustment for clinicopathological
variables, including EGFR. This study showed that
HPV-negative/EGFR-positive patients had an adjusted
13-fold increased risk of having a loco-regional failure
and more than a 4-fold increased risk of dying com-
pared with HPV-positive/EGFR-negative patients [30].
Although several preclinical studies have shown that
HPV16 E6 and E7 expression sensitizes human kerati-
nocytes to apoptosis caused by cisplatin, etoposide and
mitomycin C by mechanisms that are not fully under-
stood [27], little information is available regarding EGFR
inhibitors and HPV-related cell tumors.
The five-year survival data of the study of Bonner et al.
on RT plus cetuximab for locoregionally advanced head
and neck cancer show some interesting associations [32].Cetuximab seemed to provide the most benefit for patients
with oropharyngeal tumors, T1–3 tumors, advanced nodal
stage, and high Karnofsky performance status, characteris-
tics associated with HPV-related tumors. These subgroups
represent small numbers of patients and might represent
spurious findings, so further work should be performed to
test the consistency of these results.
Our study has some limitations, such as the retro-
spective analysis, the small sample size, the limited num-
ber of p16-positive patients (18) and the fact that p16
expression was not an independent prognostic factor in
the multivariable analysis. The retrospective setting and
the possibility of selection bias may be considered pit-
falls, and although patient characteristics between treat-
ment groups were not completely well balanced (more
women and less alcohol consumption in the group trea-
ted with RT+EFGR inhibitors), we should point that the
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N category and ECOG performance status) were well
distributed between both arms of treatment. The issue
of sample size is another limitation because the number
of p16-positive patients in each arm of treatment was
small (8 RT+EGFR and 10 RT+CT), but despite the lim-
ited sample size, the survival benefit in p16-positive
patients treated with RT+EGFR inhibitors compared
with RT+CT reached statistical significance.
Conclusions
In conclusion, this study provides the first evidence to sup-
port a better outcome for p16-positive HNSCC patients
when treated with RT combined with EGFR inhibitors vs.
RT combined with traditional cisplatin-based CT. It is
necessary to conduct specific clinical trials for p16-positive
patients to determine if RT combined with EGFR inhibitors
is the optimal approach in this growing population. Several
studies are ongoing.
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